Xencor initiates Phase 1 trial of XmAb20717 for advanced solid tumors
Xencor, a prominent biopharmaceutical company based in Monrovia, California, has recently dosed the first patient in a Phase 1 clinical trial named XmAb20717-01 (DUET-2), aimed at evaluating the efficacy of XmAb20717 in treating multiple advanced solid tumors. This marks a significant step in cancer therapy, particularly with the use of bispecific antibodies. The DUET-2 trial […]